{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T04:58:27Z","timestamp":1780808307166,"version":"3.54.1"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1245\/s10434-026-19517-0","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T12:51:36Z","timestamp":1775220696000},"page":"6604-6616","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Lymphadenectomy Considerations Beyond Standard Gastrectomy"],"prefix":"10.1245","volume":"33","author":[{"given":"Ahmed","family":"Dehal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michail N.","family":"Mavros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parisa","family":"Malekzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis","family":"Grotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett L.","family":"Ecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian E.","family":"Strong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Society of Surgical Oncology Gastrointestinal Disease Site Workgroup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremey","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Eskander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshim","family":"Kukar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richelle T.","family":"William","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia T.","family":"Orcutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"key":"19517_CR1","unstructured":"National Cancer Institute\u2019s Epidemiology and End Results Program. Cancer Stat Facts: Stomach Cancer 2024. https:\/\/seer.cancer.gov\/statfacts\/html\/stomach.html. Accessed 27 Mar"},{"key":"19517_CR2","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/s0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet. 2019;393:1948\u201357. https:\/\/doi.org\/10.1016\/s0140-6736(18)32557-1.","journal-title":"Lancet."},{"key":"19517_CR3","doi-asserted-by":"publisher","unstructured":"Japanese Gastric Cancer Treatment Guidelines 2018. 5th edn. Gastric Cancer. 2021;24:1\u201321. https:\/\/doi.org\/10.1007\/s10120-020-01042-y.","DOI":"10.1007\/s10120-020-01042-y"},{"key":"19517_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11\u201320. https:\/\/doi.org\/10.1056\/NEJMoa055531.","journal-title":"N Engl J Med."},{"key":"19517_CR5","doi-asserted-by":"publisher","unstructured":"Japanese Gastric Cancer Treatment Guidelines 2021. 6th edn. Gastric Cancer. 2023;26:1\u201325. https:\/\/doi.org\/10.1007\/s10120-022-01331-8.","DOI":"10.1007\/s10120-022-01331-8"},{"key":"19517_CR6","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1097\/SLA.0b013e318212bff6","volume":"253","author":"MA Memon","year":"2011","unstructured":"Memon MA, Subramanya MS, Khan S, Hossain MB, Osland E, Memon B. Meta-analysis of D1 versus D2 gastrectomy for gastric adenocarcinoma. Ann Surg. 2011;253:900\u201311. https:\/\/doi.org\/10.1097\/SLA.0b013e318212bff6.","journal-title":"Ann Surg."},{"key":"19517_CR7","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/s1470-2045(10)70070-x","volume":"11","author":"I Songun","year":"2010","unstructured":"Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11:439\u201349. https:\/\/doi.org\/10.1016\/s1470-2045(10)70070-x.","journal-title":"Lancet Oncol."},{"key":"19517_CR8","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/s1470-2045(06)70623-4","volume":"7","author":"CW Wu","year":"2006","unstructured":"Wu CW, Hsiung CA, Lo SS, et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol. 2006;7:309\u201315. https:\/\/doi.org\/10.1016\/s1470-2045(06)70623-4.","journal-title":"Lancet Oncol."},{"key":"19517_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/bjs.9345","volume":"101","author":"M Degiuli","year":"2014","unstructured":"Degiuli M, Sasako M, Ponti A, et al. Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer. Br J Surg. 2014;101:23\u201331. https:\/\/doi.org\/10.1002\/bjs.9345.","journal-title":"Br J Surg."},{"key":"19517_CR10","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1001\/jamaoncol.2017.0515","volume":"3","author":"SE Al-Batran","year":"2017","unstructured":"Al-Batran SE, Homann N, Pauligk C, et al. Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial. JAMA Oncol. 2017;3:1237\u201344. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0515.","journal-title":"JAMA Oncol."},{"key":"19517_CR11","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/s12885-023-10773-x","volume":"23","author":"Y Cui","year":"2023","unstructured":"Cui Y, Yu Y, Zheng S, et al. Does resection after neoadjuvant chemotherapy of docetaxel, oxaliplatin, and S-1 (DOS regimen) benefit for gastric cancer patients with single non-curable factor? A multicenter, prospective cohort study (Neo-REGATTA). BMC Cancer. 2023;23:308. https:\/\/doi.org\/10.1186\/s12885-023-10773-x.","journal-title":"BMC Cancer."},{"key":"19517_CR12","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.21037\/jgo.2017.09.01","volume":"8","author":"ZJ Brown","year":"2017","unstructured":"Brown ZJ, Hernandez JM, Ripley RT, Davis JL. Heated intraperitoneal chemotherapy and gastrectomy for gastric cancer in the U.S.: the time is now. J Gastrointest Oncol. 2017;8:1109\u201313. https:\/\/doi.org\/10.21037\/jgo.2017.09.01.","journal-title":"J Gastrointest Oncol."},{"key":"19517_CR13","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1245\/s10434-020-08739-5","volume":"28","author":"B Badgwell","year":"2021","unstructured":"Badgwell B, Ikoma N, Murphy MB, et al. A phase II trial of cytoreduction, gastrectomy, and hyperthermic intraperitoneal perfusion with chemotherapy for patients with gastric cancer and carcinomatosis or positive cytology. Ann Surg Oncol. 2021;28:258\u201364. https:\/\/doi.org\/10.1245\/s10434-020-08739-5.","journal-title":"Ann Surg Oncol."},{"key":"19517_CR14","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1245\/s10434-022-12761-0","volume":"30","author":"BL Green","year":"2023","unstructured":"Green BL, Blumenthaler AN, Gamble LA, et al. Cytoreduction and HIPEC for gastric carcinomatosis: multi-institutional analysis of two phase II clinical trials. Ann Surg Oncol. 2023;30:1852\u201360. https:\/\/doi.org\/10.1245\/s10434-022-12761-0.","journal-title":"Ann Surg Oncol."},{"key":"19517_CR15","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1200\/JCO.18.01688","volume":"37","author":"PE Bonnot","year":"2019","unstructured":"Bonnot PE, Piessen G, Kepenekian V, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis. J Clin Oncol. 2019;37:2028\u201340. https:\/\/doi.org\/10.1200\/JCO.18.01688.","journal-title":"J Clin Oncol."},{"key":"19517_CR16","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S1470-2045(15)00553-7","volume":"17","author":"K Fujitani","year":"2016","unstructured":"Fujitani K, Yang HK, Mizusawa J, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016;17:309\u201318. https:\/\/doi.org\/10.1016\/S1470-2045(15)00553-7.","journal-title":"Lancet Oncol."},{"key":"19517_CR17","doi-asserted-by":"publisher","first-page":"6295","DOI":"10.2147\/cmar.S182436","volume":"10","author":"Y Wang","year":"2018","unstructured":"Wang Y, Zhu L, Xia W, Wang F. Anatomy of lymphatic drainage of the esophagus and lymph node metastasis of thoracic esophageal cancer. Cancer Manag Res. 2018;10:6295\u2013303. https:\/\/doi.org\/10.2147\/cmar.S182436.","journal-title":"Cancer Manag Res."},{"key":"19517_CR18","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/s1470-2045(25)00027-0","volume":"26","author":"BJ van der Wilk","year":"2025","unstructured":"van der Wilk BJ, Eyck BM, Wijnhoven BPL, et al. Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trial. Lancet Oncol. 2025;26:425\u201336. https:\/\/doi.org\/10.1016\/s1470-2045(25)00027-0.","journal-title":"Lancet Oncol."},{"key":"19517_CR19","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.soc.2006.07.015","volume":"15","author":"M Feith","year":"2006","unstructured":"Feith M, Stein HJ, Siewert JR. Adenocarcinoma of the esophagogastric junction: surgical therapy based on 1602 consecutive resected patients. Surg Oncol Clin North Am. 2006;15:751\u201364. https:\/\/doi.org\/10.1016\/j.soc.2006.07.015.","journal-title":"Surg Oncol Clin North Am."},{"key":"19517_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/bjsopen\/zrad138","author":"XD Chen","year":"2024","unstructured":"Chen XD, Chen QC, Xu R, Zhao FZ. Therapeutic value of lymph node dissection for Siewert type II and III adenocarcinoma: meta-analysis. BJS Open. 2024. https:\/\/doi.org\/10.1093\/bjsopen\/zrad138.","journal-title":"BJS Open."},{"key":"19517_CR21","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.surg.2014.08.099","volume":"157","author":"Y Kurokawa","year":"2015","unstructured":"Kurokawa Y, Hiki N, Yoshikawa T, et al. Mediastinal lymph node metastasis and recurrence in adenocarcinoma of the esophagogastric junction. Surgery. 2015;157:551\u20135. https:\/\/doi.org\/10.1016\/j.surg.2014.08.099.","journal-title":"Surgery."},{"key":"19517_CR22","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/sla.0000000000003499","volume":"274","author":"Y Kurokawa","year":"2021","unstructured":"Kurokawa Y, Takeuchi H, Doki Y, et al. Mapping of lymph node metastasis from esophagogastric junction tumors: a prospective nationwide multicenter study. Ann Surg. 2021;274:120\u20137. https:\/\/doi.org\/10.1097\/sla.0000000000003499.","journal-title":"Ann Surg."},{"key":"19517_CR23","doi-asserted-by":"publisher","first-page":"e339","DOI":"10.1097\/sla.0000000000005332","volume":"277","author":"EL Vos","year":"2023","unstructured":"Vos EL, Nakauchi M, G\u00f6nen M, et al. Risk of lymph node metastasis in T1b gastric cancer: an international comprehensive analysis from the Global Gastric Group (G3) Alliance. Ann Surg. 2023;277:e339\u201345. https:\/\/doi.org\/10.1097\/sla.0000000000005332.","journal-title":"Ann Surg."},{"key":"19517_CR24","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1016\/j.gassur.2024.05.014","volume":"28","author":"Z Yu","year":"2024","unstructured":"Yu Z, Liang C, Gao J, et al. Clinicopathologic factors correlated with lymph node metastasis in gastric cancer: a retrospective cohort study involving 5606 patients. J Gastrointest Surg. 2024;28:1242\u20139. https:\/\/doi.org\/10.1016\/j.gassur.2024.05.014.","journal-title":"J Gastrointest Surg."},{"key":"19517_CR25","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1245\/s10434-025-18613-x","volume":"33","author":"H Fei","year":"2026","unstructured":"Fei H, Ren H, Wen Z, et al. Lymph node metastasis frequency and development of predictive model in T1b gastric cancer: a single-center study. Ann Surg Oncol. 2026;33:1391\u2013403. https:\/\/doi.org\/10.1245\/s10434-025-18613-x.","journal-title":"Ann Surg Oncol."},{"key":"19517_CR26","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1097\/pas.0000000000001276","volume":"43","author":"M Du","year":"2019","unstructured":"Du M, Chen L, Cheng Y, et al. Tumor budding and other risk factors of lymph node metastasis in submucosal early gastric carcinoma: a multicenter clinicopathologic study in 621 radical gastrectomies of Chinese patients. Am J Surg Pathol. 2019;43:1074\u201382. https:\/\/doi.org\/10.1097\/pas.0000000000001276.","journal-title":"Am J Surg Pathol."},{"key":"19517_CR27","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1007\/s00464-024-11517-z","volume":"39","author":"W Yu","year":"2025","unstructured":"Yu W, Xu Z, Li B, et al. Nomogram for pre-procedural prediction of lymph node metastasis in patients with submucosal early gastric cancer. Surg Endosc. 2025;39:1661\u201371. https:\/\/doi.org\/10.1007\/s00464-024-11517-z.","journal-title":"Surg Endosc."},{"key":"19517_CR28","doi-asserted-by":"publisher","first-page":"22873","DOI":"10.1038\/s41598-021-02305-z","volume":"11","author":"M Zhang","year":"2021","unstructured":"Zhang M, Ding C, Xu L, et al. A nomogram to predict risk of lymph node metastasis in early gastric cancer. Sci Rep. 2021;11:22873. https:\/\/doi.org\/10.1038\/s41598-021-02305-z.","journal-title":"Sci Rep."},{"key":"19517_CR29","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1200\/jco.21.02242","volume":"40","author":"YW Kim","year":"2022","unstructured":"Kim YW, Min JS, Yoon HM, et al. Laparoscopic sentinel node navigation surgery for stomach preservation in patients with early gastric cancer: a randomized clinical trial. J Clin Oncol. 2022;40:2342\u201351. https:\/\/doi.org\/10.1200\/jco.21.02242.","journal-title":"J Clin Oncol."},{"key":"19517_CR30","doi-asserted-by":"publisher","DOI":"10.1097\/sla.0000000000006219","author":"H Hur","year":"2024","unstructured":"Hur H, Lee YJ, Kim YW, et al. Clinical efficacy of laparoscopic sentinel node navigation surgery for stomach preservation in patients with early gastric cancer: 5-year results of the SENORITA trial. Ann Surg. 2024. https:\/\/doi.org\/10.1097\/sla.0000000000006219.","journal-title":"Ann Surg."},{"key":"19517_CR31","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1001\/jamasurg.2024.1210","volume":"159","author":"BW Eom","year":"2024","unstructured":"Eom BW, Yoon HM, Kim YW, et al. Quality of life and nutritional outcomes of stomach-preserving surgery for early gastric cancer: a secondary analysis of the SENORITA randomized clinical trial. JAMA Surg. 2024;159:900\u20138. https:\/\/doi.org\/10.1001\/jamasurg.2024.1210.","journal-title":"JAMA Surg."},{"key":"19517_CR32","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s10120-004-0274-7","volume":"7","author":"GR Blackshaw","year":"2004","unstructured":"Blackshaw GR, Stephens MR, Lewis WG, Paris HJ, Barry JD, Edwards P, Allison MC. Prognostic significance of acute presentation with emergency complications of gastric cancer. Gastric Cancer. 2004;7:91\u20136. https:\/\/doi.org\/10.1007\/s10120-004-0274-7.","journal-title":"Gastric Cancer."},{"key":"19517_CR33","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1749-7922-7-31","volume":"7","author":"P Vasas","year":"2012","unstructured":"Vasas P, Wiggins T, Chaudry A, Bryant C, Hughes FS. Emergency presentation of the gastric cancer; prognosis and implications for service planning. World J Emerg Surg. 2012;7:31. https:\/\/doi.org\/10.1186\/1749-7922-7-31.","journal-title":"World J Emerg Surg."},{"key":"19517_CR34","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3978\/j.issn.2078-6891.2011.001","volume":"2","author":"KK Tan","year":"2011","unstructured":"Tan KK, Quek TJ, Wong N, Li KK, Lim KH. Emergency surgery for perforated gastric malignancy: an institution\u2019s experience and review of the literature. J Gastrointest Oncol. 2011;2:13\u20138. https:\/\/doi.org\/10.3978\/j.issn.2078-6891.2011.001.","journal-title":"J Gastrointest Oncol."},{"key":"19517_CR35","first-page":"516","volume":"92","author":"Y Adachi","year":"1997","unstructured":"Adachi Y, Mori M, Maehara Y, Matsumata T, Okudaira Y, Sugimachi K. Surgical results of perforated gastric carcinoma: an analysis of 155 Japanese patients. Am J Gastroenterol. 1997;92:516\u20138.","journal-title":"Am J Gastroenterol."},{"key":"19517_CR36","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1053\/ejso.2000.1003","volume":"26","author":"T Lehnert","year":"2000","unstructured":"Lehnert T, Buhl K, Dueck M, Hinz U, Herfarth C. Two-stage radical gastrectomy for perforated gastric cancer. Eur J Surg Oncol. 2000;26:780\u20134. https:\/\/doi.org\/10.1053\/ejso.2000.1003.","journal-title":"Eur J Surg Oncol."},{"key":"19517_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2023.102008","volume":"51","author":"AAS Ub\u00f8e","year":"2023","unstructured":"Ub\u00f8e AAS, V\u00e5ge C, Mj\u00f8nes P, Bringeland EA, Fossmark R. Gastric remnant cancer and long-term survival in central Norway 2001 to 2016: a population-based study. Surg Oncol. 2023;51:102008. https:\/\/doi.org\/10.1016\/j.suronc.2023.102008.","journal-title":"Surg Oncol."},{"key":"19517_CR38","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.3748\/wjg.v22.i8.2424","volume":"22","author":"M Ohira","year":"2016","unstructured":"Ohira M, Toyokawa T, Sakurai K, et al. Current status in remnant gastric cancer after distal gastrectomy. World J Gastroenterol. 2016;22:2424\u201333. https:\/\/doi.org\/10.3748\/wjg.v22.i8.2424.","journal-title":"World J Gastroenterol."},{"key":"19517_CR39","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00432-011-1034-9","volume":"138","author":"F Li","year":"2012","unstructured":"Li F, Zhang R, Liang H, Liu H, Quan J, Zhao J. The pattern of lymph node metastasis and the suitability of 7th UICC N stage in predicting prognosis of remnant gastric cancer. J Cancer Res Clin Oncol. 2012;138:111\u20137. https:\/\/doi.org\/10.1007\/s00432-011-1034-9.","journal-title":"J Cancer Res Clin Oncol."},{"key":"19517_CR40","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.surg.2016.01.003","volume":"159","author":"T Irino","year":"2016","unstructured":"Irino T, Hiki N, Ohashi M, Nunobe S, Tokunaga M, Sano T, Yamaguchi T. Characteristics of gastric stump cancer: a single hospital retrospective analysis of 262 patients. Surgery. 2016;159:1539\u201347. https:\/\/doi.org\/10.1016\/j.surg.2016.01.003.","journal-title":"Surgery."},{"key":"19517_CR41","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s10120-020-01081-5","volume":"23","author":"H Katai","year":"2020","unstructured":"Katai H, Ishikawa T, Akazawa K, et al. Optimal extent of lymph node dissection for remnant advanced gastric carcinoma after distal gastrectomy: a retrospective analysis of more than 3000 patients from the nationwide registry of the Japanese Gastric Cancer Association. Gastric Cancer. 2020;23:1091\u2013101. https:\/\/doi.org\/10.1007\/s10120-020-01081-5.","journal-title":"Gastric Cancer."},{"key":"19517_CR42","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1245\/s10434-014-3633-6","volume":"21","author":"A Di Leo","year":"2014","unstructured":"Di Leo A, Pedrazzani C, Bencivenga M, et al. Gastric stump cancer after distal gastrectomy for benign disease: clinicopathological features and surgical outcomes. Ann Surg Oncol. 2014;21:2594\u2013600. https:\/\/doi.org\/10.1245\/s10434-014-3633-6.","journal-title":"Ann Surg Oncol."},{"key":"19517_CR43","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s11605-011-1804-3","volume":"16","author":"S Komatsu","year":"2012","unstructured":"Komatsu S, Ichikawa D, Okamoto K, et al. Differences of the lymphatic distribution and surgical outcomes between remnant gastric cancers and primary proximal gastric cancers. J Gastrointest Surg. 2012;16:503\u20138. https:\/\/doi.org\/10.1007\/s11605-011-1804-3.","journal-title":"J Gastrointest Surg."},{"key":"19517_CR44","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(21)00797-2.","journal-title":"Lancet."},{"key":"19517_CR45","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(17)31827-5.","journal-title":"Lancet."},{"key":"19517_CR46","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.2217\/fon-2018-0609","volume":"15","author":"K Kato","year":"2019","unstructured":"Kato K, Shah MA, Enzinger P, et al. KEYNOTE-590: phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer. Future Oncol. 2019;15:1057\u201366. https:\/\/doi.org\/10.2217\/fon-2018-0609.","journal-title":"Future Oncol."},{"key":"19517_CR47","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1158\/2159-8290.CD-21-0888","volume":"12","author":"R Kim","year":"2022","unstructured":"Kim R, An M, Lee H, et al. Early tumor-immune microenvironmental remodeling and response to first-line fluoropyrimidine and platinum chemotherapy in advanced gastric cancer. Cancer Discov. 2022;12:984\u20131001. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0888.","journal-title":"Cancer Discov."},{"key":"19517_CR48","doi-asserted-by":"publisher","unstructured":"Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202\u20139. https:\/\/doi.org\/10.1038\/nature13480.","DOI":"10.1038\/nature13480"},{"key":"19517_CR49","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1001\/jamaoncol.2016.6762","volume":"3","author":"EC Smyth","year":"2017","unstructured":"Smyth EC, Wotherspoon A, Peckitt C, et al. Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial. JAMA Oncol. 2017;3:1197\u2013203. https:\/\/doi.org\/10.1001\/jamaoncol.2016.6762.","journal-title":"JAMA Oncol."},{"key":"19517_CR50","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1245\/s10434-015-4931-3","volume":"23","author":"D Marrelli","year":"2016","unstructured":"Marrelli D, Polom K, Pascale V, et al. Strong prognostic value of microsatellite instability in intestinal type non-cardia gastric cancer. Ann Surg Oncol. 2016;23:943\u201350. https:\/\/doi.org\/10.1245\/s10434-015-4931-3.","journal-title":"Ann Surg Oncol."},{"key":"19517_CR51","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1097\/SLA.0000000000005501","volume":"277","author":"EL Vos","year":"2023","unstructured":"Vos EL, Maron SB, Krell RW, et al. Survival of locally advanced MSI-high gastric cancer patients treated with perioperative chemotherapy: a retrospective cohort study. Ann Surg. 2023;277:798\u2013805. https:\/\/doi.org\/10.1097\/SLA.0000000000005501.","journal-title":"Ann Surg."},{"key":"19517_CR52","doi-asserted-by":"publisher","first-page":"21743","DOI":"10.1038\/s41598-023-48157-7","volume":"13","author":"FF Talari","year":"2023","unstructured":"Talari FF, Bozorg A, Zeinali S, Zali M, Mohsenifar Z, AsadzadehAghdaei H, Baghaei K. Low incidence of microsatellite instability in gastric cancers and its association with the clinicopathological characteristics: a comparative study. Sci Rep. 2023;13:21743. https:\/\/doi.org\/10.1038\/s41598-023-48157-7.","journal-title":"Sci Rep."},{"key":"19517_CR53","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/SLA.0000000000002803","volume":"270","author":"YY Choi","year":"2019","unstructured":"Choi YY, Kim H, Shin SJ, et al. Microsatellite instability and programmed cell death-ligand 1 expression in stage II\/III gastric cancer: post hoc analysis of the CLASSIC randomized controlled study. Ann Surg. 2019;270:309\u201316. https:\/\/doi.org\/10.1097\/SLA.0000000000002803.","journal-title":"Ann Surg."},{"key":"19517_CR54","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.giec.2021.08.004","volume":"32","author":"W Kim","year":"2022","unstructured":"Kim W, Kidambi T, Lin J, Idos G. Genetic syndromes associated with gastric cancer. Gastrointest Endosc Clin North Am. 2022;32:147\u201362. https:\/\/doi.org\/10.1016\/j.giec.2021.08.004.","journal-title":"Gastrointest Endosc Clin North Am."},{"key":"19517_CR55","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.cgh.2023.08.028","volume":"22","author":"JN Hatton","year":"2024","unstructured":"Hatton JN, de Andrade KC, Frone MN, Savage SA, Khincha PP. Spectrum and excess risk of gastrointestinal tumors in Li-Fraumeni syndrome. Clin Gastroenterol Hepatol. 2024;22:662\u20135. https:\/\/doi.org\/10.1016\/j.cgh.2023.08.028.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"19517_CR56","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.1136\/flgastro-2022-102123","volume":"13","author":"P Edwards","year":"2022","unstructured":"Edwards P, Monahan KJ. Diagnosis and management of Lynch syndrome. Frontline Gastroenterol. 2022;13:e80\u20137. https:\/\/doi.org\/10.1136\/flgastro-2022-102123.","journal-title":"Frontline Gastroenterol."},{"key":"19517_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14041000","author":"S Kumar","year":"2022","unstructured":"Kumar S, Farha N, Burke CA, Katona BW. Upper gastrointestinal cancer surveillance in Lynch syndrome. Cancers Basel. 2022. https:\/\/doi.org\/10.3390\/cancers14041000.","journal-title":"Cancers Basel."},{"key":"19517_CR58","doi-asserted-by":"publisher","first-page":"e386","DOI":"10.1016\/S1470-2045(20)30219-9","volume":"21","author":"VR Blair","year":"2020","unstructured":"Blair VR, McLeod M, Carneiro F, et al. Hereditary diffuse gastric cancer: updated clinical practice guidelines. Lancet Oncol. 2020;21:e386\u201397. https:\/\/doi.org\/10.1016\/S1470-2045(20)30219-9.","journal-title":"Lancet Oncol."},{"key":"19517_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2021.104401","volume":"65","author":"J Garcia-Pelaez","year":"2022","unstructured":"Garcia-Pelaez J, Barbosa-Matos R, Sao Jose C, et al. Gastric cancer genetic predisposition and clinical presentations: established heritable causes and potential candidate genes. Eur J Med Genet. 2022;65:104401. https:\/\/doi.org\/10.1016\/j.ejmg.2021.104401.","journal-title":"Eur J Med Genet."},{"key":"19517_CR60","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1001\/jamasurg.2020.6155","volume":"156","author":"LA Gamble","year":"2021","unstructured":"Gamble LA, Heller T, Davis JL. Hereditary diffuse gastric cancer syndrome and the role of CDH1: a review. JAMA Surg. 2021;156:387\u201392. https:\/\/doi.org\/10.1001\/jamasurg.2020.6155.","journal-title":"JAMA Surg."},{"issue":"2","key":"19517_CR61","doi-asserted-by":"publisher","first-page":"109","DOI":"10.14735\/amko2019S109","volume":"32","author":"L Foretova","year":"2019","unstructured":"Foretova L, Navratilova M, Svoboda M, et al. GAPPS\u2013gastric adenocarcinoma and proximal polyposis of the stomach syndrome in 8 families tested at Masaryk Memorial Cancer Institute: prevention and prophylactic gastrectomies. Klin Onkol. 2019;32(2):109\u201317. https:\/\/doi.org\/10.14735\/amko2019S109.","journal-title":"Klin Onkol."},{"key":"19517_CR62","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1002\/ags3.12708","volume":"7","author":"M Iwatsuki","year":"2023","unstructured":"Iwatsuki M, Matsumoto C, Mimori K, Baba H. The comprehensive review of gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) from diagnosis and treatment. Ann Gastroenterol Surg. 2023;7:725\u201332. https:\/\/doi.org\/10.1002\/ags3.12708.","journal-title":"Ann Gastroenterol Surg."},{"key":"19517_CR63","doi-asserted-by":"publisher","first-page":"9373","DOI":"10.1007\/s00464-023-10303-7","volume":"37","author":"MK Bryant","year":"2023","unstructured":"Bryant MK, Sillcox R, Grady WM, Oelschlager BK. Laparoscopic prophylactic total gastrectomy with limited lymphadenectomy for CDH1 gene carriers. Surg Endosc. 2023;37:9373\u201380. https:\/\/doi.org\/10.1007\/s00464-023-10303-7.","journal-title":"Surg Endosc."},{"key":"19517_CR64","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1200\/JCO.23.01238","volume":"42","author":"AF Gallanis","year":"2024","unstructured":"Gallanis AF, Gamble LA, Samaranayake SG, et al. Costs of cancer prevention: physical and psychosocial sequelae of risk-reducing total gastrectomy. J Clin Oncol. 2024;42:421\u201330. https:\/\/doi.org\/10.1200\/JCO.23.01238.","journal-title":"J Clin Oncol."},{"key":"19517_CR65","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000443168","volume":"103","author":"G DelleFave","year":"2016","unstructured":"DelleFave G, O\u2019Toole D, Sundin A, et al. ENETS consensus guidelines update for gastroduodenal neuroendocrine neoplasms. Neuroendocrinology. 2016;103:119\u201324. https:\/\/doi.org\/10.1159\/000443168.","journal-title":"Neuroendocrinology."},{"key":"19517_CR66","doi-asserted-by":"publisher","first-page":"7973","DOI":"10.12998\/wjcc.v9.i27.7973","volume":"9","author":"H Koseoglu","year":"2021","unstructured":"Koseoglu H, Duzenli T, Sezikli M. Gastric neuroendocrine neoplasms: a review. World J Clin Cases. 2021;9:7973\u201385. https:\/\/doi.org\/10.12998\/wjcc.v9.i27.7973.","journal-title":"World J Clin Cases."},{"key":"19517_CR67","doi-asserted-by":"publisher","first-page":"839","DOI":"10.6004\/jnccn.2021.0032","volume":"19","author":"MH Shah","year":"2021","unstructured":"Shah MH, Goldner WS, Benson AB, et al. Neuroendocrine and adrenal tumors, version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19:839\u201368. https:\/\/doi.org\/10.6004\/jnccn.2021.0032.","journal-title":"J Natl Compr Canc Netw."},{"key":"19517_CR68","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.soc.2019.11.009","volume":"29","author":"AM Laird","year":"2020","unstructured":"Laird AM, Libutti SK. Management of other gastric and duodenal neuroendocrine tumors. Surg Oncol Clin North Am. 2020;29:253\u201366. https:\/\/doi.org\/10.1016\/j.soc.2019.11.009.","journal-title":"Surg Oncol Clin North Am."},{"key":"19517_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e20928","volume":"9","author":"L Liu","year":"2023","unstructured":"Liu L, Liu W, Jia Z, et al. Application of machine-learning algorithms to predict lymph node metastasis in gastric neuroendocrine neoplasms. Heliyon. 2023;9:e20928. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e20928.","journal-title":"Heliyon."},{"key":"19517_CR70","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/j.ejso.2020.12.015","volume":"47","author":"Y Yamagata","year":"2021","unstructured":"Yamagata Y, Yoshikawa T, Ishizu K, et al. Is lymph node dissection for neuroendocrine carcinoma of the stomach effective as it is for adenocarcinoma? Eur J Surg Oncol. 2021;47:2004\u20139. https:\/\/doi.org\/10.1016\/j.ejso.2020.12.015.","journal-title":"Eur J Surg Oncol."},{"key":"19517_CR71","doi-asserted-by":"publisher","first-page":"8641","DOI":"10.1245\/s10434-022-12582-1","volume":"29","author":"ZE Stiles","year":"2022","unstructured":"Stiles ZE, Fleming AM, Dickson PV, Tsao M, Glazer ES, Shibata D, Deneve JL. Lymph node metastases in gastrointestinal stromal tumors: an uncommon event. Ann Surg Oncol. 2022;29:8641\u20138. https:\/\/doi.org\/10.1245\/s10434-022-12582-1.","journal-title":"Ann Surg Oncol."},{"key":"19517_CR72","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.6004\/jnccn.2022.0058","volume":"20","author":"M von Mehren","year":"2022","unstructured":"von Mehren M, Kane JM, Riedel RF, et al. NCCN guidelines(R) insights: gastrointestinal stromal tumors, version 2.2022. J Natl Compr Canc Netw. 2022;20:1204\u201314. https:\/\/doi.org\/10.6004\/jnccn.2022.0058.","journal-title":"J Natl Compr Canc Netw."},{"key":"19517_CR73","first-page":"471","volume":"55","author":"M Valad\u00e3o","year":"2008","unstructured":"Valad\u00e3o M, de Mello EL, Louren\u00e7o L, Vilhena B, Romano S, Castro Ldos S. What is the prognostic significance of metastatic lymph nodes in GIST? Hepatogastroenterology. 2008;55:471\u20134.","journal-title":"Hepatogastroenterology."},{"key":"19517_CR74","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1001\/jamaoncol.2016.0256","volume":"2","author":"SA Boikos","year":"2016","unstructured":"Boikos SA, Pappo AS, Killian JK, et al. Molecular subtypes of KIT\/PDGFRA wild-type gastrointestinal stromal tumors: a report from the National Institutes of Health Gastrointestinal Stromal Tumor Clinic. JAMA Oncol. 2016;2:922\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2016.0256.","journal-title":"JAMA Oncol."},{"key":"19517_CR75","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/PAS.0b013e3182671178","volume":"37","author":"M Miettinen","year":"2013","unstructured":"Miettinen M, Killian JK, Wang ZF, et al. Immunohistochemical loss of succinate dehydrogenase subunit A (SDHA) in gastrointestinal stromal tumors (GISTs) signals SDHA germline mutation. Am J Surg Pathol. 2013;37:234\u201340. https:\/\/doi.org\/10.1097\/PAS.0b013e3182671178.","journal-title":"Am J Surg Pathol."},{"key":"19517_CR76","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s10555-019-09818-0","volume":"38","author":"P Neppala","year":"2019","unstructured":"Neppala P, Banerjee S, Fanta PT, Yerba M, Porras KA, Burgoyne AM, Sicklick JK. Current management of succinate dehydrogenase-deficient gastrointestinal stromal tumors. Cancer Metastasis Rev. 2019;38:525\u201335. https:\/\/doi.org\/10.1007\/s10555-019-09818-0.","journal-title":"Cancer Metastasis Rev."},{"key":"19517_CR77","unstructured":"Board PDQATE. Gastrointestinal Stromal Tumors Treatment (PDQ\u00ae): Health Professional Version. PDQ Cancer Information Summaries. National Cancer Institute (US); 2002."},{"key":"19517_CR78","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3748\/wjg.v10.i1.5","volume":"10","author":"AM Al-Akwaa","year":"2004","unstructured":"Al-Akwaa AM, Siddiqui N, Al-Mofleh IA. Primary gastric lymphoma. World J Gastroenterol. 2004;10:5\u201311. https:\/\/doi.org\/10.3748\/wjg.v10.i1.5.","journal-title":"World J Gastroenterol."},{"key":"19517_CR79","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.suc.2016.11.012","volume":"97","author":"N Ikoma","year":"2017","unstructured":"Ikoma N, Badgwell BD, Mansfield PF. Multimodality treatment of gastric lymphoma. Surg Clin North Am. 2017;97:405\u201320. https:\/\/doi.org\/10.1016\/j.suc.2016.11.012.","journal-title":"Surg Clin North Am."},{"key":"19517_CR80","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3748\/wjg.v17.i6.697","volume":"17","author":"P Ghimire","year":"2011","unstructured":"Ghimire P, Wu GY, Zhu L. Primary gastrointestinal lymphoma. World J Gastroenterol. 2011;17:697\u2013707. https:\/\/doi.org\/10.3748\/wjg.v17.i6.697.","journal-title":"World J Gastroenterol."},{"key":"19517_CR81","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/01.sla.0000129356.81281.0c","volume":"240","author":"SS Yoon","year":"2004","unstructured":"Yoon SS, Coit DG, Portlock CS, Karpeh MS. The diminishing role of surgery in the treatment of gastric lymphoma. Ann Surg. 2004;240:28\u201337. https:\/\/doi.org\/10.1097\/01.sla.0000129356.81281.0c.","journal-title":"Ann Surg."},{"key":"19517_CR82","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1046\/j.1365-2559.2002.01411.x","volume":"40","author":"YH Ko","year":"2002","unstructured":"Ko YH, Han JJ, Noh JH, Ree HJ. Lymph nodes in gastric B-cell lymphoma: pattern of involvement and early histological changes. Histopathology. 2002;40:497\u2013504. https:\/\/doi.org\/10.1046\/j.1365-2559.2002.01411.x.","journal-title":"Histopathology."},{"key":"19517_CR83","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1002\/1097-0142(19820315)49:6<1135::aid-cncr2820490612>3.0.co;2-e","volume":"49","author":"ID Fleming","year":"1982","unstructured":"Fleming ID, Mitchell S, Dilawari RA. The role of surgery in the management of gastric lymphoma. Cancer. 1982;49:1135\u201341. https:\/\/doi.org\/10.1002\/1097-0142(19820315)49:6%3c1135::aid-cncr2820490612%3e3.0.co;2-e.","journal-title":"Cancer."},{"key":"19517_CR84","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1056\/NEJMra2102568","volume":"386","author":"D Rossi","year":"2022","unstructured":"Rossi D, Bertoni F, Zucca E. Marginal-zone lymphomas. N Engl J Med. 2022;386:568\u201381. https:\/\/doi.org\/10.1056\/NEJMra2102568.","journal-title":"N Engl J Med."},{"key":"19517_CR85","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/bf02303698","volume":"2","author":"KC Conlon","year":"1995","unstructured":"Conlon KC, Casper ES, Brennan MF. Primary gastrointestinal sarcomas: analysis of prognostic variables. Ann Surg Oncol. 1995;2:26\u201331. https:\/\/doi.org\/10.1007\/bf02303698.","journal-title":"Ann Surg Oncol."},{"key":"19517_CR86","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/0305-7372(83)90007-5","volume":"10","author":"YT Lee","year":"1983","unstructured":"Lee YT. Leiomyosarcoma of the gastrointestinal tract: general pattern of metastasis and recurrence. Cancer Treat Rev. 1983;10:91\u2013101. https:\/\/doi.org\/10.1016\/0305-7372(83)90007-5.","journal-title":"Cancer Treat Rev."},{"key":"19517_CR87","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.94111","volume":"17","author":"J Mendes","year":"2025","unstructured":"Mendes J, Viveiros F, Veiga M, Fazeres F, Vasconcelos E. Gastric leiomyosarcoma: a case report and literature review. Cureus. 2025;17:e94111. https:\/\/doi.org\/10.7759\/cureus.94111.","journal-title":"Cureus."},{"key":"19517_CR88","doi-asserted-by":"publisher","first-page":"6815","DOI":"10.1038\/s41467-025-62056-7","volume":"16","author":"A Zaanan","year":"2025","unstructured":"Zaanan A, Didelot A, Broudin C, et al. Longitudinal circulating tumor DNA analysis during treatment of locally advanced resectable gastric or gastroesophageal junction adenocarcinoma: the PLAGAST prospective biomarker study. Nat Commun. 2025;16:6815. https:\/\/doi.org\/10.1038\/s41467-025-62056-7.","journal-title":"Nat Commun."},{"key":"19517_CR89","doi-asserted-by":"publisher","DOI":"10.1200\/po.22.00420","volume":"6","author":"BM Huffman","year":"2022","unstructured":"Huffman BM, Aushev VN, Budde GL, et al. Analysis of circulating tumor DNA to predict risk of recurrence in patients with esophageal and gastric cancers. JCO Precis Oncol. 2022;6:e2200420. https:\/\/doi.org\/10.1200\/po.22.00420.","journal-title":"JCO Precis Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19517-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-19517-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19517-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T04:02:20Z","timestamp":1780804940000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-19517-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":89,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["19517"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-19517-0","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]},"assertion":[{"value":"9 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Vivian Strong reports the following conflicts: Astra Zeneca \u2013 speaking honoraria and DaVinci \u2013 one time consultant. Other coauthors report no relevant financial disclosures.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}